ERCC1 and neoplasm: Considering these data, a prospective phase II clinical trial to assess the efficacy of selecting chemotherapy regimens (with or without platinum, and with or without gemcitabine) based on ERCC1 and RRM1 tumor expression in adjuvant setting of NSCLC has been planned by the Southwest Oncology Group (SWOG).